Biocon Biologics launches product for autoimmune diseases in Australia
PTI
Last Updated:
New Delhi, Jul 23 (PTI) Biocon on Wednesday said its subsidiary Biocon Biologics has launched a product for the treatment of autoimmune diseases like rheumatoid arthritis, in the Australian market.
The company has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia, the company said in a regulatory filing.
Nepexto will be promoted by Generic Health, a local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in that country, it added.
Etanercept is a fusion-protein that inhibits tumour necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
Since receiving EU marketing authorisation in 2020, Nepexto has earned broad adoption across Europe.
Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen its immunology offering, it said.
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Hyderabad Pharma Firm To Make Drug For Hard-To-Treat Bladder Cancer After Local Trials Waiver
For Indian patients battling aggressive bladder cancer driven by specific gene changes, a vital treatment may soon be available. Citing an 'unmet medical need" India's top drug advisory panel has approved a pharmaceutical firm's request to make and sell erdafitinib tablets in India by skipping a local third-phase trial but needing a post-launch fourth phase study. Hyderabad-based Natco Pharma has presented the proposal for the grant of permission to manufacture and market erdafitinib in three different strengths along with the 'justification" for a waiver on local third-phase clinical trials, as per the minutes of the meeting of the technical committee dated July 17. 'After detailed deliberation, the committee opined that there is an unmet medical need for the proposed indication in the country," said the minutes, which were accessed by News18. 'The committee recommended for the grant of permission to manufacture and market the drug Erdafitinib Tablet 3 mg, 4 mg and 5 mg with local Phase III clinical trial waiver." This marks a significant shift from the 2023 stance, when the subject expert committee (SEC), functioning under Central Drugs Standard Control Organisation (CDSCO), had rejected Natco's request for a Phase-III waiver. After reviewing the bioequivalence data, the SEC asked the company to 'submit the Phase-III clinical trial protocol before the committee for further consideration". That earlier decision underscored the caution about approving cancer treatments without robust local safety and efficacy data. According to the GLOBOCAN 2020 database, bladder cancer is the 17th most common malignancy in India. The five-year prevalence appears to be 3.57 per 1,00,000 population, leading to about 11,000 deaths each year. The incidence of bladder cancer is higher in males as compared to females. Data shows that bladder cancer incidence does vary across India. Among males, Delhi had the highest incidence rates followed by Thiruvananthapuram and Kolkata, and the lowest rate was in Dibrugarh. When it comes to females, the rate is highest in Delhi followed by Mumbai and Mizoram, respectively, and lowest in Barshi. Over time, bladder cancer incidence has increased in Delhi, Bengaluru and Mumbai, while it has decreased in Chennai. WHAT MAKES ERDAFITINIB IMPORTANT? Erdafitinib is a targeted therapy that inhibits the fibroblast growth factor receptor (FGFR) – a key driver of rapid tumour growth in certain bladder cancers. The FGFR gene gives the body instructions to make FGFR proteins, which sit on the surface of cells. These proteins receive growth signals (called fibroblast growth factors) and tell the cell when to grow, divide, or repair itself. On January 19, 2024, the US FDA approved erdafitinib, sold under the brand name Balversa, developed by Janssen Biotech, a Johnson & Johnson company. The drug has been approved for adults with advanced or metastatic bladder cancer that has certain FGFR3 gene changes, confirmed by an approved test. It can be used if the cancer has worsened after at least one previous systemic treatment. It is not meant for patients who could still benefit from PD-1 or PD-L1 immunotherapy and have not yet tried it. ONCOLOGISTS WELCOME THE MOVE According to the sellers on the online platform Indiamart, the bottle containing 56 tablets of 4mg Erdafitinib is sold at Rs 7,000, which is Rs 125 per tablet. With local manufacturing, however, the cost is expected to drop by more than 50 per cent. 'It's a good drug for bladder cancer patients with locally advanced disease not responding to chemotherapy. This is targeted therapy that blocks fibroblast growth factor receptor (FGFR). This fibroblast growth factor helps cancer grow fast. This medicine blocks this growth and helps control cancer," said Dr Satya Prakash Yadav, director of paediatric haematology-oncology and bone marrow transplant at Medanta Hospital. Similarly, Dr Pragya Shukla, who leads the clinical oncology department at Delhi State Cancer Institute, said the drug is for FGFR-altered metastatic urothelium, which has failed on multiple lines of chemotherapy and has shown benefits in overall survival in this particular group of patients. As the panel cited 'unmet demand", Dr Shukla said: 'The drug should definitely benefit a particular group of patients waiting for a targeted therapy." WHAT COMES NEXT? If the technical committee's recommendation is adopted into a final CDSCO order, Natco Pharma may roll out erdafitinib across India – provided it submits a robust Phase-IV study protocol within three months of approval. A fourth phase trial is the stage of research that happens after a drug has been approved by regulators and is already being sold in the market. It is also called post-marketing surveillance or post-approval study. It can reveal safety issues, interactions, or benefits that did not appear in smaller or shorter trials before, and at times lead to changes in how the drug is prescribed – or even withdrawal if serious risks are found.
Economic Times
an hour ago
- Economic Times
Dollar holds gains ahead of inflation data; Aussie awaits RBA
The U.S. dollar remained stable as markets awaited a crucial consumer inflation report, influencing expectations for potential Federal Reserve interest rate cuts. The Australian dollar held steady before the Reserve Bank of Australia's policy decision. Traders are closely watching inflation data for clues about the Fed's next move, especially concerning a possible rate cut in September. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The U.S. dollar held steady on Tuesday, with markets braced for a key consumer inflation report later in the day that could shape expectations for Federal Reserve interest rate cuts The Australian dollar was steady hours before a policy decision by the Reserve Bank of Australia The U.S. dollar index - which measures the currency against six counterparts, including the euro and yen - was steady at 98.497 as of 0046 GMT, after advancing 0.5% over the past two to that, the dollar had retreated as U.S. President Donald Trump's dovish-leaning pick to replace a Fed governor, and similarly inclined potential candidates for chairman, led traders to increase easing addition, Fed officials have sounded increasingly uneasy about the labour market, signalling their openness to a rate cut as soon as inflation could cement bets for a reduction next month, but if signs emerge that Trump's tariffs are fuelling price pressures, that might keep the central bank on hold for currently put the odds of a quarter-point cut on September 17 at about 89%."Risk-reward heading into U.S. CPI this week is for a modest USD bounce as any upside surprise will challenge market pricing of almost a full cut by September," TD Securities strategists wrote in a research note."A downside surprise, on the other hand, is unlikely to move Fed pricing and the USD as much," they said."The reasoning is that for the Fed to consider an outsized cut of 50 basis points, the catalyst will be further deterioration in the labour market and not a downside CPI miss."Economists polled by Reuters expect core CPI to have risen 0.3% in July, pushing the annual rate higher to 3%.The greenback rose 0.1% to 148.28 yen on Tuesday. The euro was flat at $ dollar on Monday largely ignored Trump's signing an executive order extending a pause in sharply higher tariffs on Chinese imports for another 90 days, a move that some market participants said was the United States and China seeking to close a deal averting triple-digit import tariffs, a U.S. official told Reuters that chip makers Nvidia and AMD had agreed to allocate 15% of China sales revenues to the U.S. government, aiming to secure export licences for yuan was flat at 7.1935 per dollar in offshore Aussie fetched $0.6518 , little changed from Monday with economists and investors widely expecting a quarter-point rate reduction from the RBA, after second-quarter inflation came in weaker than expected and the jobless rate hit a 3-1/2-year the risk of a surprise has been amplified by a change in decision-making at the central bank, and many traders were caught out when the policy board refrained from lowering rates last month. Cryptocurrency bitcoin was unchanged at around $118,845, after it climbed as high as $122,308.25 on Monday that took it close to the all-time peak of $123,153.22 from mid-July.
News18
2 hours ago
- News18
Explained: How The Latest Tax Bill 2025 Changes House Property Income Rules
Last Updated: Revised Income Tax Bill clarifies 30% deduction post-municipal tax and extends pre-construction interest benefit to let-out homes New Income Tax Bill 2025: Clause 22 of the revised New Income Tax Bill, 2025, has addressed two long-pending ambiguities in the taxation of 'Income from House Property." 1. Standard Deduction Clarification The Bill now explicitly states that the 30% standard deduction will be calculated on the net annual value—that is, after deducting municipal taxes from the annual value determined under Clause 21. In the earlier draft, it was unclear whether the deduction applied before or after municipal tax deduction, raising concerns it could be taken on the gross annual value. The Lok Sabha Select Committee recommended this amendment to preserve fairness and align the new law with existing provisions under Sections 23 and 24 of the Income-tax Act, 1961. Under current law, interest on borrowed capital for acquiring or constructing a property can be claimed as a deduction, including pre-construction interest spread over five equal annual instalments. This benefit applies to both self-occupied and let-out properties. What It Means for Homeowners Tax experts say these clarifications prevent potential disputes and ensure the computation process remains consistent with long-established practice. Experts Take: Chartered Accountant Abhishek Soni, co-founder of Tax2Win, said: 'A let-out house property is one that is rented out or leased to another party. The rental income from such a property is taxable under 'Income from House Property'. Individuals can claim tax deductions on municipal taxes paid, standard deduction (30% of net annual value), and interest on home loans." CA (Dr.) Suresh Surana explained to The Economic Times: Under the current Income-tax Act, 1961, Sections 23 and 24 govern the computation of 'Income from House Property." Section 23 allows municipal taxes actually paid to be deducted from the annual value to arrive at the net annual value, and Section 24(a) allows a standard deduction of 30% on this net value. However, the original draft of the Income-tax Bill, 2025, did not clarify whether the 30% deduction was to be applied before or after municipal taxes, raising concerns it might be calculated on gross annual value. The Select Committee's recommendation now ensures the 30% standard deduction applies to the annual value after municipal taxes—aligning with existing practice. About the Author Aparna Deb Aparna Deb is a Subeditor and writes for the business vertical of She has a nose for news that matters. She is inquisitive and curious about things. Among other things, financial markets, economy, More Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. Get in-depth analysis, expert opinions, and real-time updates—only on News18. Also Download the News18 App to stay updated! view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
